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Oncolytic virotherapy of cancer is among the innovative modalities being under develop-
ment and especially promising for targeting tumors, which are resistant to conventional
treatments. Presently, at least a dozen of viruses, belonging to nine different virus
families, are being tested within the frames of various clinical studies in cancer patients.
Continuously growing preclinical evidence showing that the autonomous rat parvovirus
H-1 (H-1PV) is able to kill tumor cells that resist conventional treatments and to achieve
a complete cure of various human tumors in animal models argues for its inclusion in the
arsenal of oncolytic viruses with an especially promising bench to bedside translation
potential. Oncolytic parvovirus safe administration to humans relies on the intrinsic
preference of these agents for quickly proliferating, metabolically, and biochemically
disturbed tumor versus normal cells (tumor selectivity or oncotropism). The present
review summarizes and discusses (i) preclinical evidence of H-1PV innocuousness for
normal cells and healthy tissues in vitro and in animals, respectively, (ii) toxicological
assessments of H-1PV mono- or combined therapy in tumor-bearing virus-permissive
animal models, as well as (iii) historical results of experimental infection of human cancer
patients with H-1PV. Altogether, these data argue against a risk of H-1PV inducing
significant toxic effects in human patients. This highly favorable safety profile allowed the
translation of H-1PV preclinical research into a Phase I/IIa clinical trial being currently
in progress.
Keywords: oncolytic virotherapy of cancer, oncolytic viruses, oncotropism, oncoselectivity, parvovirus H-1,
preclinical assessment, toxicological studies, safety profile
The Concept of Oncolytic Virotherapy for Cancer Treatment
Oncolytic virotherapy is one of the innovative modalities under development to target tumors
that are refractory to conventional surgical and radio/chemotherapeutic treatments. While the
possibility of using some viruses to fight cancer was put forward at the beginning of the twentieth
century, the field underwent striking revival in the last three decades, along with the development
of molecular virology and genetic engineering. The term “oncolytic viruses” (OVs) designates
non-pathogenic live viruses that can infect and kill malignant cells without causing any harm to
normal tissues. Because of space constraints, the concept of oncolytic virotherapy will be only briefly
outlined below, and citations will be limited to some recent review articles (Liu et al., 2007; Haseley
et al., 2009; Meerani and Yao, 2010; Wong et al., 2010; Friedman et al., 2012; Russel et al., 2012;
Singh et al., 2012; Ahmed, 2013; Bartlett et al., 2013; Goldufsky et al., 2013; Vacchelli et al., 2013;
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Lichty et al., 2014; Vähä-Koskela and Hinkkanen, 2014; Woller
et al., 2014), to which readers are referred for further details.
Cancer virotherapy is based on four main properties of OVs, as
depicted in Figure 1.
(i) Oncoselectivity is an obvious sine qua non-condition for
oncolytic virotherapy. The selectivity of OV infection and
replication for tumor cells is an inherent feature of cer-
tain virus species, or a result of virus adaptation or tar-
geted genetic engineering. This oncotropism reflects the
dependence of distinct step(s) of the OV life-cycle on
tumor-specific molecular (epi)genetic alterations. It results
in particular from the fact that, on the one hand, most
tumors have evolved mechanisms to suppress responses
used by normal cells to limit virus infection, and on the other
hand, signaling pathways promoting the growth of tumor
cells favor virus replication as well.
(ii) Oncolysis can be induced in a direct way by OVs as a result
of virus replication and/or expression of viral cytotoxic gene
products in infected tumor cells. A major asset of OVs lies
in their multimechanistic mode of malignant cell killing,
which differs from the cell death processes triggered by con-
ventional anti-cancer agents. This peculiarity can be ratio-
nalized by the virus need to prevent premature cytopathic
FIGURE 1 | Direct and indirect anti-tumor effects of oncolytic viruses
(OVs). Normal cells resist OV infection because of viral life-cycle blockage
prior to the induction of cytopathic effects. In contrast, OVs can disturb at
least three cell types within the tumor. Infected cancer cells undergo an
immunogenic type of death (direct oncolysis), which is sometimes (e.g., figure)
but not always accompanied by virus production; this oncolysis leads to the
activation of various immune cells (green), irrespective of their direct virus
infection, thereby priming anti-cancer immune responses. Furthermore, the
(abortive) OV infection of immune and endothelial cells inside the tumor results
in cytotoxic cytokine production and anti-vascular/angiogenic effects,
respectively, which both contribute to virus-mediated oncolysis in an indirect
way. Uninfected tumor cells can also serve as targets for these indirect
oncolytic effects.
effects (CPE) from interfering with virus production, and is
therapeutically exploited to overcome the resistance devel-
oped by many tumor cells to conventional therapies.
(iii) Indirect bystander oncolytic effects also contribute to a signif-
icant extent to the oncosuppressive activity of OVs, which
canmediate in this way the killing of uninfected cancer cells.
These indirect OV-induced oncolytic effects can result from
tumor vasculature disruption and angiogenesis, release of
toxic cytokines from infected tumor-resident or infiltrating
immune cells, and even more importantly, from systemic
anti-tumor immune responses. Indeed, the tumor cell death
caused by OVs is often immunogenic, leading to the acti-
vation of innate immune cells and to efficient presentation
of tumor-associated antigens eliciting adaptive anti-tumor
immunity. Oncolytic virotherapy can be considered from
either virocentric or immunocentric points of view, depend-
ing on whether emphasis is placed on direct virus-induced
oncolysis or on virus-mediated stimulation of anti-tumor
immune responses. In animal models, both mechanisms
appear to act in combination, while having different relative
weights depending on the individual target tumor.
(iv) Replication-competent OVs are used in the hope of achiev-
ing intratumoral amplification of the initial inoculum and
production of progeny virions, which can spread to non-
infected tumor cells, including distant metastases, until the
entire tumor tissue is affected. While this multiplication has
been observed in some animal tumor models, extensive OV
spread at sites of tumor growth remains to be documented
in clinical settings.
The potential of the oncolytic virotherapeutic approach is sup-
ported by substantial evidence of OV-induced oncosuppressive
effects at both preclinical and clinical levels. More than a thou-
sand patients have now been treated with OVs by intratumoral
injection and/or intravenous infusion during Phase I–III clinical
trials. Compelling evidence of OV-induced anti-cancer immunity
was obtained for a recombinant oncolytic herpes simplex virus
by showing that its intratumoral administration to patients with
metastatic malignant melanoma led to the complete regression of
injected and uninjected tumors in 8/50 treated patients (Kaufman
et al., 2010). It has also been shown that an oncolytic vaccinia
virus can reach tumor sites by extravasating from tumor blood
vessels (Breitbach et al., 2013), lending credit to the use of sys-
temic OV administration for metastases targeting. Indeed, in
an earlier clinical trial, the authors have shown that a vaccinia
vaccine-derived oncolytic poxvirus used as a vehicle for delivery
and expression of transgenes, achieves cancer-selective replication
after intravenous infusion in patients with advanced, treatment-
refractory solid tumors (Breitbach et al., 2011). OV spread at
tumor sites following systemic administration has been clinically
demonstrated with yet another virus. An oncolytic reovirus was
intravenously infused before surgery to resect colorectal cancer
liver metastases. Reovirus immune cell carriage and delivery as
well as recovery of replicating virus from the tumor was achieved,
confirming intravenous reovirus targeting ofmetastatic colon car-
cinoma (Adair et al., 2012). The OVs, which are most advanced in
clinical developments, include oncolytic herpes simplex, vaccinia,
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reo-, and adenoviruses, with the latter being licensed in China
for use against head and neck cancer (Garber, 2006). The pace
of clinical activities in the field has accelerated considerably, and
OVs belonging to not less than nine different virus families are
presently the subject of various clinical studies in cancer patients.
These clinical studies confirmed that OVs, as expected from
their oncoselectivity, can be safely administered to humans.
Indeed, the clinical tolerability of OVs has overall been excellent,
and dose-limiting toxicities were only rarely observed. Interest-
ingly, the most common adverse effects – transient flu-like symp-
toms – do not overlap with those caused by other anti-cancer
agents, supporting the possibility of combining oncolytic virother-
apy with current therapeutic modalities. Since future trials will
likely use higher OV doses, it is not guaranteed that effective
virotherapy will always be devoid of toxicity. However, this con-
cern has to be balanced against the risk of current therapies, which
approach the upper limit of tolerability. One OV-specific safety
risk relates to viral spread from the treated patient to contacts.
However, OV transmission has not been observed so far, although
limited virus shedding in bodily fluids has occasionally been
reported (Makower et al., 2003; Pecora and Lorence, 2007; Hughes
et al., 2014).
Among OVs, the autonomous rat parvovirus H-1, the subject
of this review, deserves special consideration as candidate anti-
cancer agent. Continuously growing preclinical evidence demon-
strates the ability of this virus to kill tumor cells that resist con-
ventional anti-cancer treatments and to achieve a complete cure
of various tumors in animal models, importantly, while being
innocuous for non-transformed cells and normal tissues (Rom-
melaere et al., 2010). Currently, parvovirus H-1 is in a Phase
I/IIa clinical trial designed to document its maximum tolerated
dose and safety profile in patients with recurrent glioblastoma
multiforme.
The Oncolytic H-1 Parvovirus
The oncolytic H-1 parvovirus (H-1PV) belongs to the fam-
ily Parvoviridae, subfamily Parvovirinae, genus Protoparvovirus,
and species Rodent protoparvovirus 1 (Figure 2). Like all par-
voviruses, H-1PV is a small (25 nm in diameter) non-enveloped
virus characterized by an icosahedral capsid and a linear single-
stranded DNA genome of approximately 5,000 nucleotides (Tat-
tersall, 2006). Viral genomic DNA comprises two transcription
units that are controlled by the P4 and P38 promoters and code
for the non-structural (NS) and structural (VP) viral proteins,
respectively (Cotmore and Tattersall, 2014; Cotmore et al., 2014).
The NS protein NS1 plays a major role in the viral life-cycle,
by being essential for viral DNA replication, gene expression,
and virus-induced cytotoxic effects (Nüesch, 2006; Hristov et al.,
2010; Nüesch et al., 2012; Li et al., 2013). H-1PV replicates
autonomously in target cells, in close dependence on cellular
proliferation and differentiation factors (Cornelis et al., 2006). The
natural host of H-1PV is the rat, infection of whom can either
be pathogenic and even lethal (in immunologically unprotected
fetuses and neonates) or clinically inapparent (in adult animals).
As documented below, under in vitro conditions, the virus pref-
erentially replicates in and kills transformed or tumor-derived
rat and human cell cultures, without inducing cytotoxicity in
their corresponding non-transformed/non-malignant counter-
parts (Rommelaere et al., 2005, 2010). Moreover, the above obser-
vations illustrative of parvovirus H-1 oncoselectivity have been
further extended to animal models, in which H-1PVwas reported
to efficiently suppress tumor formation and to cause striking
regression of established tumors (oncosuppression, see below)
(Rommelaere and Cornelis, 1991).
Mechanisms of Rodent Protoparvovirus
Oncoselectivity
Parvovirus intrinsic oncoselectivity is a complex phenomenon
based in part on multiple tumor cell-specific determinants, which
are under-represented in non-malignant cells. The availability
of cellular replication and transcription factors, the overexpres-
sion of cellular proteins known to interact with parvoviral ones
(with NS1, in particular), the activation of metabolic pathways
involved in the functional regulation of NS1, are all contributing
to parvovirus preference for tumor, and not for normal cells. The
molecular pathways involved in H-1PV tumor cell targeting are
overviewed in a recent publication from our laboratory (Nüesch
et al., 2012), while the most important in vitro and animal studies
providing evidence of parvovirus oncoselectivity and innocuous-
ness in a non-malignant environment are summarized in the
present review (see following sections). Although it is feasible to
attenuate PVs by genetic engineering (Daeffler et al., 2003), the use
of these viruses as anti-cancer agents is not based on this strategy
since the innocuousness of wild-type PVs to normal tissues avoids
the need to attenuate undesirable toxicity.
To our knowledge, there is no evidence to indicate that PV
preference for infecting tumor cells results from a higher compe-
tence of these cells for virus binding and internalization. Instead,
neoplastic cells appear to provide an intracellular milieu that is
especially permissive for at least part or the full course of the PV
life-cycle. This higher permissiveness of tumor cells cannot be
traced back to a single factor, but rather involves multiple cellular
factors that control different steps of the PV life-cycle and each
give infection a distinct boost (Figure 2). These factors are thus
likely to cooperate in promoting virus infection, with the impact
of later-acting factors depending on the completion of earlier steps
in the viral cycle. A number of tumor cells provide all the factors
that are necessary for full virus replication, resulting in progeny
particle production and cell lysis. Some other tumor cells are
semi-permissive (and get killed in the absence of progeny virions
release), and a few remain resistant to infection. It should also be
stated that man is not the natural host of rodent PVs, and normal
human cells may pose different and/or additional restrictions to
PV infection, compared to rodent cells. This can be exemplified
by our recent work showing that the PDK1/PKC/PKB cascade –
which regulates the functioning of the replicative and cytotoxic
PV protein NS1 – is induced by the mouse parvovirus MVM
in mouse but not in human cells (Lachmann et al., 2008; Bär
et al., 2015). In consequence, the constitutive activation of this
cascade through an unconventional mechanism in human tumor
cells represents a human-specific determinant of the oncoselectiv-
ity of PVs.
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FIGURE 2 | Characteristics of H-1 parvovirus. (A) In silico model of H-1PV
capsid surface showing the two, three, and fivefold axes of symmetry (Allaume
et al., 2012). (B) Simplified viral gene expression map. The viral single-stranded
(ss) DNA genome ends in unique palindromic sequences (Pal), which serve as
self-priming origins of replication for the synthesis of double-stranded replication
forms/transcription templates. Transcription is controlled by the P4 and P38
promoters that are indicated by arrows and direct expression of non-structural
(NS) and capsid (VP) proteins, respectively. (C) Simplified scheme of the viral
life-cycle depicting the main steps leading to virus production and induction of
cytopathic effects (CPE). Known and putative oncogenic
transformation-stimulated steps are indicated by full and dashed red circles,
respectively.
Most of the cellular determinants of PV oncoselectivity, as
identified so far, control the viral life-cycle in a positive way
(Figure 3).
 Some of these factors are not strictly tumor-specific but
characteristic of proliferating cells. Examples thereof are
cyclin A/CDK2 (Bashir et al., 2000; Adeyemi and Pin-
tel, 2012) and E2F (Deleu et al., 1999), which are cellu-
lar S-phase markers and control the conversion of the PV
single-stranded DNA genome into double-stranded replica-
tive forms/transcription templates, and the activation of
the PV early promoter P4, respectively. Both factors are
thus essential for the onset of PV replication, contributing
to the S-phase dependency of these viruses. Although a
fraction of tumor cells can be dormant and some normal
tissues are rapidly self-renewing, the proliferating compo-
nent of many tumors distinguishes them from essentially
quiescent surrounding normal tissues, offering a target for
PV infection and thereby contributing to the enhancement
of virus replication and CPE in neoplastic versus normal
tissues.
 Other determinants of PV oncoselectivity are more specific
for malignantly transformed cells in which they are over-
expressed or activated as a result of (epi)genetic alterations
occurring in these cells. A few factors of this type have been
shown to promote distinct steps of the PV life-cycle. These
steps include:
(i) viral entry: PKCα- and CDK1-dependent nuclear envelope
breakdown (Porwal et al., 2013).
(ii) viral gene expression: activation of the early PV promoter P4
byEts andATF transcription factors (Perros et al., 1995; Fuks
et al., 1996).
(iii) viral DNA amplification: activation of the PV replicative pro-
tein NS1 through PDK1, PKC, and radixin (Rdx)-mediated
phosphorylation (Dettwiler et al., 1999; Lachmann et al.,
2003, 2008; Nüesch et al., 2009; Bär et al., 2015); HMGB1-
dependent initiation of DNA amplification from the right-
hand viral origin (Cotmore and Tattersall, 1998; Cotmore
et al., 2000); facilitation of viral replication through an ATM
kinase-mediated DNA damage response (Adeyemi et al.,
2010).
(iv) viral progeny capsid assembly: Raf-1 phosphorylation-
dependent nuclear transport of capsid intermediates (Riolo-
bos et al., 2010).
(v) virions maturation: XPO1, PKB, PKC, and Rdx-dependent
egress (Eichwald et al., 2002; Nüesch et al., 2009; Bär et al.,
2013, 2015).
(vi) cytopathic effects: expression of potential PV targets, includ-
ing distinct tropomyosin (TPM) isoforms (Nüesch and
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FIGURE 3 | Putative cell determinants of PV oncoselectivity. Indicated
steps of the PV life-cycle (rectangles) were shown to be controlled by cellular
factors (circles) known to be regulated at gene amplification, expression, and
functional levels by cell proliferation (blue) and oncogenic transformation
(red). The list of factors is not exhaustive and exemplifies candidate
mediators of the enhanced permissiveness of neoplastic cells for PV
infection. Evidence of the contribution of these factors to PV oncotropism is
experimental for a few of them (PDK1, PKCη, Ets, ATF, Raf-1) but
circumstantial for the others. For more details, see main text (pp. 4–5).
CDK2, cyclin-dependent kinase 2; PDK1, phosphoinositide-dependent
kinase 1; PKC, protein kinase C; Rdx, radixin; HMGB1, high-mobility group
box protein 1; ATM, ataxia-telangiectasia mutated protein; Raf-1, rapidly
accelerated fibrosarcoma-1 protein; XPO1, exportin-1; PKB, protein kinase
B; E2F, transcription factor E2F; Ets, E26 transformation-specific
transcription factor; ATF, activating transcription factor; CKII, casein kinase II;
TPM, tropomyosin; CTSB, cathepsin B.
Rommelaere, 2007), or checkpoint factors, e.g., cyclin B1
(Adeyemi and Pintel, 2014); production of cytotoxic effec-
tors, such as cathepsin B (CTSB) (Di Piazza et al., 2007) and
CKII (Nüesch and Rommelaere, 2006); PDK1 and PKCι-
dependent activation ofNS1 cytotoxic function (Nüesch and
Rommelaere, 2006; Bär et al., 2015).
The role played by some of these factors in the oncotropism
of PVs was supported by the fact that their helper function was
stimulated in transformed cells, rescuing at least to some extent
the viral life-cycle defect in normal cells.
The oncoselectivity of a number of OVs can also be traced
back to the frequent deficiency, in tumor cells, of mechanisms
that allow normal cells to counteract virus infection, in particular,
the type I interferon and stress responses. Along this line, the
mouse Protoparvovirus MVMwas shown to both induce the type
I interferon response and be sensitive to it in normal mouse cells,
while a still elusive evasion mechanism appeared to be triggered
by the virus in their transformed counterparts, preventing inter-
ferons from being produced (Grekova et al., 2010a,b). It follows
that in this system, PV oncoselectivity consisted of an additional
component, namely, the absence of negative modulators of PV
infection in transformed cells. It is unclear whether these data can
be extrapolated to human neoplastic versus normal cells. Various
human tumor cells were recently reported to fail to develop a
type I interferon response upon PV (including H-1PV) infection.
However, this failure was also observed in normal human cells
(Paglino et al., 2014), questioning whether the interferon response
plays any role in the oncoselectivity of rodent protoparvoviruses
in human cells. It should be again recalled in this regard that man
is not the natural host of rodent protoparvoviruses, and some of
the factors limiting the viral life-cyclemay therefore differ between
cells from natural and heterologous hosts.
In vitro Evidence of H-1PV Oncoselectivity
The pioneering observations demonstrating that H-1PV fails
to induce CPE in normal human (e.g., embryonic kidney and
amnion) cultures were published by Toolan and Ledinko (1965).
H-1PV innocuousness for non-malignant cells has been later
confirmed in a number of in vitro studies, as summarized in
Table 1.
For example, H-1PV infection was quantitatively compared in
a series of non-permanent cultures of normal human (fore)skin
fibroblasts and their respective SV40-transformed counterparts.
Although the virus was adsorbed and taken up by both normal
and transformed cells, only in the latter, H-1PVwas able to induce
killing and progressive culture degeneration. In addition, a strik-
ing difference in the capacity of normal versus transformed fibrob-
lasts to support viral DNA and protein synthesis was found. Only
the SV40-transformants, but not their non-transformed counter-
parts, could provide the intracellular environment required to
support the completion of H-1PV lytic cycle and the release of
infectious progeny virions (Chen et al., 1986; Faisst et al., 1989).
Similar observations were made when established keratinocyte
cell lines derived from human squamous cell carcinoma were
used. Efficient virus-induced killing and productive infection
were seen in human tongue, cheek, supraglottis, and face squa-
mous cell carcinoma-derived keratinocytes. In contrast, normal
human epidermal cells isolated from healthy adult breast and used
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TABLE 1 | In vitro evidence of H-1PV oncoselectivity.
Transformed/tumor cells (Tu) Normal cells (N) Tu versus N sensitization
to H-1PV infection
Reference
Spontaneously transformed human
amnion
Normal human amniona  CPE in Tu
 No toxicity in N
Toolan and Ledinko (1965)
SV40-transformed human (fore)skin
fibroblasts
Normal human (fore)skin fibroblastsa  Efficient Tu killing: active DNA and
protein synthesis; abundant NS1
phosphorylation; productive Tu
infection
 Minor cytotoxicity, no killing and
abortive N infection
Chen et al. (1986, 1989), Faisst et al.
(1989), Dupressoir et al. (1989), Van
Pachterbeke et al. (1993, 1997), and
Muharram et al. (2010)
Squamous cell carcinoma-derived
human keratinocytes
Normal human breast skin
keratinocytesa
Breast carcinoma-derived human
epithelial cells
Normal human mammary gland
epithelial cellsa
Hepatoma-derived human cells Normal human hepatocytesa  Tu killing through apoptosis
 No NS1 expression and no N killing
Moehler et al. (2001)
Glioma-derived human cells Normal human astrocytes and gliaa  Cathepsin-mediated Tu death
 Low NS1 levels and no N killing
Di Piazza et al. (2007) and Lacroix
et al. (2010, 2014)
EBV-transformed and lymphoma/
leukemia-derived human immune cells
Normal human and rat immune cellsa  Efficient Tu killing and productive Tu
infection
 Retained N viability and abortive N
infection
Moehler et al. (2003), Angelova et al.
(2009a), Grekova et al. (2010a,b),
Moralès et al. (2012), and Raykov
et al. (2013)
aNon-established (low-passage-number) cultures.
CPE, cytopathic effect; EBV, Epstein–Barr virus.
after one passage in vitro (low-passage-number cultures) were
resistant to H-1PV infection (Chen et al., 1989; Faisst et al., 1989).
In another study, established lines or low-passage-number in vitro
cultures derived from either human breast tumor specimens or
normal peritumoral breast tissue from the same patient were used
to evidence H-1PV oncoselectivity. The striking oncolytic virus-
induced cytotoxic effects observed in tumor-derived cultures were
absent in the respective normal tissue-derived controls (Dupres-
soir et al., 1989; Van Pachterbeke et al., 1993, 1997). Furthermore,
in invasive breast carcinoma-derived cells, in contrast to normal
breast epithelium, a distinct phosphorylation pattern of the major
viral cytotoxic protein NS1 was documented (Muharram et al.,
2010). Selective H-1PV-induced killing of human liver carcinoma
cells versus normal hepatocytes was also reported. Low-passage
number cultures established from healthy liver tissue failed to
support NS1 expression and were therefore refractory to lytic
infection (Moehler et al., 2001). In order to prepare a preclinical
platform for H-1PV clinical application in brain tumor patients
and patients with other nervous system-originating tumors, virus
toxicity was evaluated in normal primary human infant astrocytes,
glial cells, and cortical neurons as well. The data showed that
the morphology, metabolic activity, and membrane integrity of
the above cells remained unaltered even after high-dose H-1PV
infection. Whereas in malignant neuroblastoma cells, abundant
NS1 expression was observed and found to result in cellular G2
arrest, no or only low NS1 levels could be detected in normal
astrocytes and mixed glial cultures. Indeed, although the latter
could take a recombinant EGFP-transducing virus up, transduc-
tion efficiency was more than 10-fold lower than in the neu-
roblastoma cell line reported to be the least sensitive to H-1PV-
induced cytotoxicity (Lacroix et al., 2010, 2014). In agreement
with these data, virus innocuousness for normal human adult
astrocytes was also described. It was shown that while triggering
lysosomal membrane permeabilization and cathepsin-mediated
death in human glioma-derived cells, H-1PV was non-toxic for
normal astrocyte cultures (Di Piazza et al., 2007). Experimental
data illustrating absence of H-1PV-induced toxicity in normal
cells came also from studies using preclinical non-Hodgkin lym-
phoma models. In contrast to Burkitt lymphoma-derived cells,
which were highly susceptible to H-1PV-induced killing and sup-
ported high levels of progeny virions production, non-malignant
B lymphocytes, including normal memory B cells, were shown to
resist infection, with minor toxicity being observed only when
cultures were infected with high H-1PV doses. Since normal
B lymphocytes were unable to express EGFP after transduction
with a recombinant EGFP-transducing virus, this minimal toxic
effect was unrelated to viral gene expression (Angelova et al.,
2009a).Normal human immune cell resistance to PV infection was
reported by other authors as well. Immature or mature dendritic
cells and monocytes were shown to retain viability after H-1PV
challenge (Moehler et al., 2003), while, in contrast, the human
histiocytic lymphoma-derived monocyte cell line U937 is among
the in vitro systems being the most sensitive to H-1PV lytic
effects (Rayet et al., 1998). Proofs of PV innocuousness for normal
peripheral blood mononuclear cells are of particular importance
in view of current and future H-1PV clinical applications. It was
shown that although basal levels of viral DNA replicative forms
were detected in the latter cells, no productive infection, even after
mitogen stimulation, could be observed (Grekova et al., 2010a,b).
Similar results were reported by Moralès et al. (2012) and Raykov
et al. (2013).
In vivo Evidence of H-1PV Oncoselectivity
After the in vitro experiments using different primary and low-
passage-number cultures demonstrated that H-1PV infection of
normal human cells is abortive, does not result in cell death and
induces no orminor CPE (see above), various animal tumormod-
els were next explored in our laboratory to test PV oncoselectivity
under in vivo conditions. The most extensive animal studies were
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performed using two tumor models, namely glioma and pancre-
atic ductal adenocarcinoma (PDAC), which are distinguished by a
dismal prognosis and represent potential targets for H-1PV-based
oncolytic virotherapy clinical applications. Rats, i.e., the natural
permissive host of the virus, were engrafted with the respective
tumors, and a long-term follow-up of the animals was performed
after H-1PV treatment, in order to assess the tumor-suppressing
capacity of the virus, and to reveal any signs of virus-induced
toxicity and/or other adverse effects.
Glioma
Only about 50% of the patients with malignant brain tumors
of glial origin survive 1 year after initial diagnosis. Furthermore,
standard treatment options lead to only modest improvements
in glioma outcome (Stummer et al., 2006). Oncolytic H-1PV,
whose capacity to selectively kill glioma-derived cells through a
cathepsin-mediated mechanism was demonstrated in vitro (Di
Piazza et al., 2007), is believed to represent a promising thera-
peutic alternative. In this regard, experimental evidence obtained
in our laboratory showing that intracerebral or systemic H-1PV
injection leads to glioma regression in immunocompetent rats
bearing orthotopic autologous RG-2 tumors and in immunodefi-
cient animals implantedwith humanU87 gliomaswithout causing
any toxic side effects, is ofmajor preclinical importance (Di Piazza
et al., 2007; Geletneky et al., 2010; Kiprianova et al., 2011). These
effects could not only be achieved by direct local intratumoral
therapy but also after intravenous and even intranasal virus inocu-
lation, although significantly higher virus doses had to be used for
systemic application. The effect of intracerebral H-1PV injection
applied to healthy or glioma-bearing rats on CTSB activity was
investigated by Di Piazza et al. (2007). In healthy brains, CTSB
activity was found to be very low and not significantly affected by
H-1PV treatment. In contrast, inH-1PV-treated gliomas a striking
enhancement of CTSB activity was detected, together with an
increase in the total amount of tumor-associated enzyme. Histo-
logical examination of H-1PV-treated gliomas raised in immuno-
competent rats (Geletneky et al., 2010) demonstrated that, in
addition to causing remission and improving animal survival, H-
1PV treatment was not associated with normal brain tissue or
other organs damage andwas accompanied by onlyminor signs of
inflammation. In agreement with previous in vitro and in vivo data
(Di Piazza et al., 2007), CTSB activation was observed only in H-
1PV-infected tumor cells but not in the surrounding peritumoral
tissue. Parvoviral DNA could be detected in the tumor and in the
peritumoral brain tissue 48 h post infection (p.i.). Virus spreading
further increased with time and at 72 h p.i. viral DNA could
additionally be detected in the contralateral brain hemisphere, in
the cerebellum, and in distant organs (heart, lungs, liver, spleen,
and kidneys), yet only transiently since no viral DNA could be
revealed in any normal tissue 2weeks p.i. Virus transcription and
NS1 accumulationwere strongly restricted to the tumor remnants,
while undetectable in surrounding normal tissues, thus arguing
for the selective H-1PV replication in tumor cells. To confirm
this statement, virus replication was compared in two groups of
animals, i.e., in glioma-bearing and in healthy control rats. The
infectious virus yield in the brain ofH-1PV-treated tumor-bearing
rats was two orders of magnitude higher than in the brain of
control animals, which were tumor-free but have been injected
with the same amount of virus. This preferential replication of H-
1PV in the neoplastic tissue, without inducing histopathological
changes in normal brain tissue, provided convincing evidence that
H-1PV preserves the oncotropism displayed in cell cultures under
in vivo conditions as well (Geletneky et al., 2010).
In an immunodeficient rat model of human glioma, both intra-
tumoral and multiple systemic (intravenous) H-1PV administra-
tions were tested and shown to result in tumor suppression with-
out being accompanied by any treatment-associated side effects.
All animals subjected to H-1PV virotherapy remained active and
gaining weight until the end of the observation period (Geletneky
et al., 2010). Expression of the PV protein NS1 was detected
in the necrotic tumor areas but not in the surrounding normal
brain tissue, in agreement with the observations made in glioma-
bearing immunocompetent animals (see above). The work of
Geletneky et al. further raised the question whether an intranasal
H-1PV application might also achieve therapeutic efficiency and
suppress the growth of human glioma xenografts in immunod-
eficient rats. As reported by Kiprianova et al. (2011), a single
intranasal virus instillation led to significant glioma regression
and animal survival prolongation, without any toxicity for all but
tumor tissues. Indeed, all virus replicationmarkers were expressed
exclusively in the tumor. These results suggest a safe and efficient
alternative to H-1PV administration via the standard invasive
intracranial route.
Pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma is one of the most lethal
gastrointestinal malignancies, causing every sixth cancer-related
death in Europe (Jemal et al., 2007). The disease is highly resistant
to current treatments: surgical resection, which achieves the best
long-term survival so far, is feasible in only a minority of patients
(Finlayson and Birkmeyer, 2003). Oncolytic H-1PV infection of
PDAC-derived cells in vitro was shown to result in efficient virus-
induced cell death, even when the cells were resistant to standard
chemotherapeutics, e.g., gemcitabine (Angelova et al., 2009b).
Furthermore, H-1PV capacity to suppress PDAC was also studied
in vivo. In a syngeneic orthotopic rat model of PDAC, a single
intratumoral H-1PV injection was applied 2weeks after implan-
tation of rat pancreatic carcinoma cells into the pancreas. Virus
expression assessment demonstrated that H-1PV was expressed
selectively in tumor as opposed to normal tissues. An initial burst
of virus expression in tumor and surrounding pancreatic tissue
was observed shortly after virus injection. H-1PV transcripts were
also detected in lymphoid organs. From day 10 onwards, virus
expression faded in normal pancreatic and other distant visceral
tissues but remained persisting in the tumor (Angelova et al.,
2009b). In an immunodeficient environment, a similar selective
tumor targeting and absence of toxicity were observed in PDAC-
bearing H-1PV-treated nude rats (Li et al., 2013).
In another study, human cervical carcinoma xenograft-bearing
nude rats were used to demonstrate a virus dose-dependent tumor
growth arrest and regression. NS1 expression was detected only
in the kidneys and at very low levels. Remarkably, no weight loss
or other adverse effects were documented in any of the treated
animals (Li et al., 2013).
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Recently, two large-scale animal experiments using virus-
permissive immunocompetent rats were initiated in order to pro-
vide further preclinical proofs of H-1PV favorable safety profile.
The virus was applied intravenously to healthy rats as either a sin-
gle high dose or multiple injections. Virus doses were considered
equivalent or higher than those resulting from viral amplification
after infection of brain tumors. It is known that the rat is the
natural host ofH-1PVand the lattermay persist in normal rat pop-
ulations by amechanismnot yet known. This persistence indicates
that also non-tumor-bearing rats are capable for parvovirus repli-
cation, making this animal model a suitable choice for the detec-
tion of possible side effects of H-1PV therapeutic application.
Irrespective of the administration regimen used, animal mortality
ormacroscopic organ changeswere not observed.Minimal diffuse
bile tract hyperplasia and germinal center development in the
spleen were detected after multiple H-1PV applications. However,
liver changes were reversible within a 2-week recovery period. No
virus-induced toxic effects could be revealed by measuring blood
parameters (hematology, chemistry, coagulation). In agreement
with in vitro data, blood mononuclear cells showed no functional
alterations after virus injection, and measurable cytokine release
could be detected. H-1PV treatment led to the development of
IgG antibodies. The virus was shed mainly via feces (Geletneky
et al., 2015a). Furthermore, the same authors demonstrated that
H-1PV is non-pathogenic in adult rats and infection does not
affect central or autonomous nervous system functions, even after
a direct injection into the brain (Geletneky et al., 2015b).
Taken together, the above described data provide experimen-
tal evidence of the oncoselectivity of H-1PV in adult animals
from its natural host, the rat, resulting in tumor suppression
in absence of any pathological signs (Table 2). This innocuous-
ness was also shown in young rats (Jacoby and Ball-Goodrich,
1995; Gaertner et al., 1996), in agreement with previous stud-
ies showing that pathological effects could only be observed if
infection of the animals took place within the first few days after
birth (Jacoby et al., 1979). Overall, this favorable safety profile
supports the further translation of H-1PV applications into the
clinic.
H-1PV Anti-Tumor Efficacy Assessment
Using Xenografts Models in
Non-Permissive Mice
Additional studies (summarized in Table 3) were carried out to
test the suppressive activity of H-1PV on human tumor xenografts
in immunodeficient recipient mice. Since the mouse is a non-
permissive host for H-1PV, these studies are not informative
regarding the oncoselectivity of H-1PV, but are much relevant for
the assessment of the suppressing capacity of the virus against
human tumor targets.
H-1PV capacity to inhibit the growth of human tumors xeno-
transplanted in recipient immunocompromised mice was first
documented by Dupressoir et al. (1989) and further substantiated
by Faisst et al. (1998). Dupressoir et al. reported that both local
(intratumoral) and systemic (intravenous) virus application lead
to significant human mammary carcinoma growth suppression
and, in some cases, reversion, without any detectable infection-
associated deleterious side effects. In the work of Faisst et al.,
quickly growing subcutaneous carcinomas were established by
implantation of human cervical carcinoma cells into immunod-
eficient SCID mice. Tumor-bearing animals were subsequently
intratumorally injected with different H-1PV doses. Intratumoral
H-1PV gene expression and dose-dependent tumor regression
were observed. This study provided the experimental evidence
showing that a single local H-1PV injection is sufficient to induce
regression, in an immunodeficient recipient environment, of cer-
tain human solid carcinomas.
Similar observations were made by Angelova et al. (2009a)
in a human lymphoma model. A single intratumoral H-1PV
TABLE 2 | In vivo evidence of H-1PV oncoselectivity.
Tumor (Tu) H-1PV adm.
route
Normal tissue (N)a Tu versus N sensitization
to H-1PV infection
Reference
Rat/human pancreatic
carcinoma
i.t. Normal pancreatic and other
visceral tissues
 Long-lasting H-1PV expression in Tu
 Transient H-1PV expression in N; no
virus-induced changes in blood, liver, and
kidney clinical parameters
Angelova et al. (2009b) and Li
et al. (2013)
Rat/human glioma i.t. Normal brain and other visceral
tissues
 Late H-1PV expression in residual Tu;
Tu-dependent H-1PV production in brain
Di Piazza et al. (2007),
Geletneky et al. (2010), and
Kiprianova et al. (2011)
i.v.
i.n.  Transient virus genome detection, no late virus
expression and no pathological alterations in N
Human cervical
carcinoma
i.t. Normal visceral tissues  Selective NS1 expression in Tu
 No weight loss or other side effects
Li et al. (2013)
Immunocomp. Tu-free
rats
i.v. Visceral tissues  Broad organ distribution and time-dependent
decrease of H-1PV genomes
Geletneky et al. (2015a,b)
i.c.
 No or minimal and reversible toxicological
changes
aTreated animals were immunocompetent (no tumor or rat tumor grafts) or nude (human tumor xenografts) rats.
i.t., intratumoral; i.v., intravenous; i.n., intranasal; i.c., intracerebral.
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TABLE 3 | H-1PV-induced suppression of human tumor xenografts in mouse models.
Tumor entity (tumor model) H-1PV-induced anti-tumor effects Reference
Breast carcinoma (HMEC HBL100 cells s.c. implanted in nude
mice)
Tumor growth suppression and complete remission with no
recurrence in 50% of the virus-treated animals
Dupressoir et al. (1989)
Cervical carcinoma (HeLa cells s.c. implanted in SCID mice) Complete tumor regression after high virus dose application Faisst et al. (1998)
Burkitt lymphoma (Namalwa cells s.c. implanted in SCID mice) Efficient tumor regression and necrosis. Virus-induced
effects also after application at late disease stages
Angelova et al. (2009a)
Gastric carcinoma (SGC-7901 cells or MKN28, SGC7901, MKN45
cells transfected with NS1-expressing plasmid, s.c. implanted in
nude mice)
Tumor growth suppression by in vivo virus infection or ex
vivo NS1 transduction
Zhang et al. (1997) and
Wang et al. (2012)
Pancreatic carcinomaa (human BxPC-3 cells s.c. implanted in
nude mice; PDAC operational material s.c. implanted in SCID mice)
H-1PV dose-dependent tumor growth delay Angelova et al. (2009b) and
Li et al. (2013)
a Implantation of non-established (patient-derived) tumor material.
HMEC, human mammary epithelial cells; s.c., subcutaneously; PDAC, pancreatic ductal adenocarcinoma.
TABLE 4 | Safety of H-1PV-based combinatorial treatments.
Tumor entity H-1PV combination
partner
Cooperative anti-neoplastic effects Oncoselectivity Reference
Pancreatic
carcinoma
Gemcitabine Enhanced effectiveness of combinative
treatment in in vivo tumor suppression
 No H-1PV-induced changes in blood-borne
bone marrow activity
Angelova et al. (2009b)
 Unaffected kidney and liver functions
VPAa Effective H-1PV dose in vivo much
reduced when VPA added to treatment
 Selective tumor targeting
 No weight loss
Li et al. (2013)
Cervical carcinoma VPA Synergistic tumor growth arrest in vivo  No other signs of toxicity
a Implantation of non-established (patient-derived) tumor material.
VPA, valproic acid.
injection in humanBurkitt lymphoma-bearing SCIDmice resulted
in quick tumor regression. Moreover, it was shown that low H-
1PV doses can achieve a strong therapeutic effect as well, even
when the virus was applied at advanced disease stages. Histo-
chemical analyses demonstratedH-1PV spreading to distant, non-
virus-treated tumors, in addition to intratumoral replication and
protein expression in virus-treated tumor tissues.
Wang et al. (2012) reported that in an in vivo human gastric
carcinoma model the ex vivo-induced NS1 expression in poorly
differentiated gastric cancer cells prevents them from forming
tumors in nude mice. This study was in agreement with an earlier
report (Zhang et al., 1997) showing that intratumoral H-1PV
application to human gastric carcinoma-bearing mice results in
efficient tumor inhibition. Importantly, this oncosuppression was
not accompanied by any toxic side reactions, even when the
virus was applied as long as twice per week for 3weeks. Simi-
lar lack of toxicity was observed after an intraperitoneal animal
treatment.
Tumor regression and complete remission in human pancreatic
carcinoma-bearing nude mice (Angelova et al., 2009b) or
NOD/SCID mice (Li et al., 2013) were observed after the
critical H-1PV dose was reached in a virus dose-escalation
experiment. This regression was not associated with detectable
toxicity. Importantly, pancreatic carcinoma patient-derived
primary tumor material was used in the study by Li et al.
(2013).
Preclinical Testing of H-1PV-Based
Combinatorial Treatments
In order to evaluate the cooperative capacity of H-1PV and
gemcitabine for suppressing pancreatic carcinoma growth in an
orthotopic rat model, tumor-bearing animals were sequentially
treated first with gemcitabine and 2weeks later with H-1PV in
a two-step protocol (Table 4). Since the two agents induce dif-
ferent death pathways (apoptosis and cathepsin-mediated cell
death, respectively), H-1PV-triggered oncolysis is expected to cir-
cumvent the antiapoptotic features (i.e., gemcitabine resistance)
acquired by many tumor cells during PDAC progression. The
data have indeed demonstrated that the anti-PDAC potential of
the drug was significantly improved when parvovirus was added
to the treatment. The combined treatment was not accompanied
by additive toxicity, as illustrated by the results of an extensive
toxicological assessment carried out in this model (Angelova
et al., 2009b). Rat bone marrow, liver, and kidney functions
were monitored by measuring clinically relevant makers. The
blood-borne markers of bone marrow activity were unaffected,
except for the gemcitabine-induced drop in the reticulocyte and
monocyte levels. Bilirubin, aspartate aminotransferase (ASAT),
and alanine aminotransferase (ALAT) levels were elevated in both
untreated and gemcitabine-treated groups of animals, reflecting
the low-grade lytic processes typical of the livers of PDAC-bearing
rats. H-1PV application as a second-line treatment restored the
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levels of these markers to their respective normal physiologi-
cal ranges. Creatinine levels remained stable after the combi-
natorial treatment, showing an unaltered kidney clearance. It
was concluded from the above toxicological assessments that the
blood-borne marker variations detected were fully attributable to
gemcitabine treatment and were not aggravated by subsequent
H-1PV administration.
Similar observations were made when established PDAC or
cervical carcinoma cells, as well as primary PDAC patient-derived
tumormaterial, were used for implantation into immunodeficient
rats or NOD/SCID mice, respectively (Li et al., 2013), in order to
assess the anti-tumor efficacy and biosafety of H-1PV combined
with valproic acid (VPA). VPA belongs to the class of histone
deacetylase (HDAC) inhibitors and has been shown to reinforce
the cytotoxicity of many OVs, including the vesicular stomatitis
virus (Alvarez-Breckenridge et al., 2012), herpes simplex virus
(Otsuki et al., 2008), and adenoviruses (Van Oosten et al., 2007),
by inhibiting the expression of cellular genes involved in antiviral
immune responses and/or by stimulating the expression of genes
required for the viral life-cycle (Nguyen et al., 2010). In vitro, VPA
has been shown to enhance H-1PV NS1-mediated cytotoxicity
through increased protein acetylation and upregulated transcrip-
tional activity (Li et al., 2013). In agreement with in vitro data,
H-1PV treatment in vivo followed by VPA administration, was
devoid of weight loss or other signs of toxicity, and resulted in syn-
ergistic tumor regression and survival prolongation. In addition,
this combinatorial approach allowed reduction of H-1PV doses to
a level, which is suboptimal in a monotherapeutical setting.
Altogether, preclinical data convincingly argue against a sig-
nificant risk of oncolytic parvovirus H-1 inducing severe toxic
effects when applied to the human patient. Moreover, H-1PV
treatment is unlikely to pose a risk of insertionalmutagenesis since
autonomous parvoviruses are not known to integrate into the
host cell genome (Richards and Armentrout, 1979; Ron and Tal,
1985). This highly favorable safety profile (Figure 4) together with
prominent anti-cancer activities justify H-1PV consideration as
mono-, combined, or second-line treatment alternative to current
conventional toxic strategies.
Clinical Evidence of H-1PV Tolerability
Despite frequent H-1PV isolation from cancer patients’ tissues
and transplantable tumors or as a contaminant of human tumor-
derived cell lines in 1970s (Toolan et al., 1960), all attempts
to isolate the virus from normal non-malignant human tissues
failed (Toolan et al., 1962; Rommelaere and Tattersall, 1989).
No convincing experimental evidence of an association between
any human disease and a previous H-1PV infection could be
found either. Initial indications of a possible role of H-1PV in
gestational problems were not confirmed by subsequent studies,
which failed to reveal the presence of H-1PV-specific antibod-
ies or H-1PV virions in sera or tissue specimens obtained after
spontaneous human abortions (Monif et al., 1965; Neuman et al.,
1970).
Important early clinical evidence showing that H-1PV appli-
cation in humans is well tolerated and devoid of side toxic-
ity was provided after experimental infection of human can-
cer patients under a compassionate use agreement. In the pio-
neering study by Toolan et al. (1965), two patients (a 12-
and 13-year-old girl) with advanced disseminated osteosar-
coma were intramuscularly inoculated with H-1PV at a dose
of approximately 1 109 plaque-forming units (pfu) of a
non-GMP-virus formulation. In one of the patients, a direct
virus injection into the tumor of the right hip area was
also applied. One of the patients developed fever of up to
38.5°C within the first 10 days after virus administration,
yet it was not clearly attributable to the virus inoculation
because of the presence of a concomitant urinary tract infec-
tion. Body temperature returned to normal after 5 days. The
patient was discharged at day 15 without any additional clin-
ical symptoms but she died of tumor progression shortly
after hospital readmission at day 38 after H-1PV treatment.
The second patient suffering from advanced metastatic dis-
ease did not experience any virus treatment-associated side
effects. In both patients, H-1PV injection led to an extensive
viremia and production of H-1PV-specific neutralizing antibod-
ies. Overall, no virus-induced organ-specific side effects could
FIGURE 4 | Preclinical evidence of H-1PV safety.
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be observed and H-1PV safety and tolerability was considered as
good in both patients.
In a later study, which took place in France within the frame
of a clinical trial entitled “Phase I clinical study on possible use
of H-1 parvovirus in cancer treatment,” 12 patients with skin
metastases originating from different types of solid tumors (breast
adenocarcinoma, melanoma, lung large cell carcinoma, pancre-
atic carcinoma, and kidney leiomyosarcoma) were subjected to
an intralesional dose-escalation (1 108, 1 109, 1 1010 pfu)
H-1PV treatment (Le Cesne et al., 1993). The virus was admin-
istered repeatedly, with 10-day treatment-free intervals. Serocon-
version was detected at days 10–15 after the first virus injection.
Only a moderate fever up to approximately 38°C (in 3 out of
the 12 patients), an isolated increase of creatinine and gamma-
glutamyl transferase (GGT) but no other H-1PV-associated toxic
side effects could be observed, arguing for an excellent safety
profile of this oncolytic virus in humans. It is also noteworthy that
in two out of seven breast carcinoma patients stable disease was
documented throughout the observation period. The presence of
virus DNA/proteins in tumor extracts was investigated in four
subjects and in all of them viral genomes/proteins could be found
after administration ofH-1PV in both target lesions (metastases to
which the virus was administered) and in control lesions (metas-
tases distant from the site of injection). This confirmed a systemic
exposure to the virus as already demonstrated by viremia.
With the support from this encouraging safety data in humans,
a next clinical trial with H-1PV in patients with malignant brain
tumorswas planned and initiated (Geletneky et al., 2012, 2014a,b).
This trial used three modes of virus application that were not
tested in 1965 and 1993 reports, namely intratumoral injection,
injection directly into the brain parenchyma bordering the tumor,
and intravenous injections. From the aspect of safety and tolera-
bility, these routes of parvovirus administration were potentially
more challenging since active virus particles in the central ner-
vous system (CNS) could lead to encephalitis or meningitis, and
an intravenous infusion might result in a more rapid systemic
exposure compared to the H-1PV release into the circulation
after intramuscular, subcutaneous, or intracutaneous injection.
The trial was planned as a dose-escalation trial at dose ranges
of 1 106, 5 107, and 1 109 pfu. The H-1PV preparation was
produced according toGMP standards thereby providing certified
virus concentrations and purity.
The initial treatment was by intratumoral injection of half of
the total dose per patient followed by a 9-day observation period
in which the virus could interact with the tumor. Tumor resection
was performed at day 10 and the second half of the dose was given
by multiple injections into the tumor-surrounding brain. Three
patients per dose groupwere treated and, for safety reasons, a time
interval of 28 days (between the first and the second patient) or of
18 days (between the second and the third patient of one group)
was allowed. All virus injections were well tolerated without any
virus-associated side effects or pathology. Some adverse effects
were detected but they were rated unrelated to virus treatment and
no dose-limiting toxicity has been found. We did not detect any
signs of fever or flu-like symptoms and in particular no signs of
CNS pathology. Measurements of viral genomes in blood showed
positive results in the intermediate-dose and high-dose group
indicating penetration of H-1PV through the blood–brain barrier,
again with no signs of systemic toxicity.
After the safety data of the intratumoral patient arm had been
reviewed by external experts and by the responsible federal agency
(Paul-Ehrlich Institut, Langen, Germany), the permission was
granted to move on to the intravenous trial arm (Geletneky et al.,
2014a,b). Here, the patients were injected with a total dose of
5 107 or 1 109 pfu of H-1PV. All patients received daily virus
infusions of 10% of the total dose at days 1 through 5, followed
by a 4-day recovery period. At day 10, surgery and intraparenchy-
mal injection of the second half of the planned dose of H-1PV
were performed, as in the first trial arm. Also, after intravenous
injection, we did not observe any side effects, in particular, no
fever and no signs of typical virus infections. The pharmacokinetic
measurements showed measurable concentrations of H-1PV over
the first 5 days (and in some patients for another one), and virus
DNA was constantly present in the 22 h period between the daily
injections indicating continuous exposure.
Another important aspect of the safety of H-1PV treatment is
biosafety and possible virus shedding by treated patients. There-
fore, patients were hospitalized under quarantine conditions until
they had generated an antibody response or were found to be
negative for H-1PV in shedding samples (feces, urine, and saliva).
Only small amounts of virus DNA could be detected in some feces
probes while saliva and urine were constantly negative. It is still
unknown whether the positive test results are indicative of active
and infectious virus or of virus nucleic acids only.
In conclusion, based on three applications in humans, H-1PV
can be considered safe and well tolerated at least to a cumulative
dose of 1 109 pfu. Flu-like symptoms can occur under treatment
but this could not be confirmed in the last trial with GMP-virus.
Thus, it cannot be ruled out that these symptoms were related to
impurities of the virus preparation and not caused by the virus
itself. Another consequence of the current safety data is that the
need for patients to be kept under isolation should be reconsidered
for future trials.
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